In dogs with atopic skin disease, is lokivetmab more effective than oclacitinib in reducing the score of a recognised scoring system?
PICO question In dogs with atopic skin disease, is lokivetmab more effective than oclacitinib in reducing the Canine Atopic Dermatitis Lesion Index score (or some other recognised scoring system)? Clinical bottom line Category of research question Treatment The number and type of...
Main Author: | Bonnie Yuan Tone Cheung |
---|---|
Format: | Article |
Language: | English |
Published: |
RCVS Knowledge
2022-06-01
|
Series: | Veterinary Evidence |
Subjects: | |
Online Access: | https://veterinaryevidence.org/index.php/ve/article/view/569 |
Similar Items
-
Establishment of an Intradermal Canine IL-31-Induced Pruritus Model to Evaluate Therapeutic Candidates in Atopic Dermatitis
by: Jason Pearson, et al.
Published: (2023-05-01) -
Use of Cytopoint in the Allergic Dog
by: Margaret Gober, et al.
Published: (2022-07-01) -
Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis
by: Marike Visser, et al.
Published: (2022-03-01) -
Dog Owners’ Perceptions of the Convenience and Value of Chewable Oclacitinib: Quantitative Survey Data from an International Survey
by: Andrea Wright, et al.
Published: (2024-03-01) -
A 3-Year Case Report on an Atopic Patient with a Caninised Monoclonal Antibody Treatment
by: Petrou P.
Published: (2022-03-01)